 BURLINGAME, Calif.--BUSINESS WIRE--Humanigen, Inc. Nasdaq: HGEN Humanigen, a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate, lenzilumabTM, today announced that the Companys management will present at the PNC Bank Solebury Trout COVID Webinar and LD Micro Investor Conference on December 15, 2020. Cameron Durrant, MD, MBA, chief executive officer of Humanigen, will provide an o 